UB Paderborn / Katalog / Suche / in CDI

On the microstructure control of the bendability of advanced high strength steels

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2018-09, Vol.735, p.89-98

2018

Link zum Volltext

Verfügbarkeit prüfen

On the correlation between fracture toughness and crash resistance of advanced high strength steels

Engineering fracture mechanics, 2019-01, Vol.205, p.319-332

2019

Link zum Volltext

Verfügbarkeit prüfen

Fracture Resistance of Advanced High-Strength Steel Sheets for Automotive Applications

Metallurgical and materials transactions. A, Physical metallurgy and materials science, 2021-02, Vol.52 (2), p.840-856

2021

Link zum Volltext

Verfügbarkeit prüfen

Microstructural effects on fracture toughness of ultra-high strength dual phase sheet steels

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2021-01, Vol.802, p.140631, Article 140631

2021

Link zum Volltext

Verfügbarkeit prüfen

Experimental issues in the instrumented 3 point bending VDA238-100 test

IOP conference series. Materials Science and Engineering, 2020-11, Vol.967 (1), p.12079

2020

Link zum Volltext

Verfügbarkeit prüfen

P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Breast (Edinburgh), 2023-04, Vol.68, p.S123-S124

2023

Link zum Volltext

Verfügbarkeit prüfen

Changes in ctDNA levels established with the untargeted mFAST-SeqS method reflect response to therapy in metastasized breast cancer patients

European journal of cancer (1990), 2016-07, Vol.61, p.S205-S206

2016

Link zum Volltext

Verfügbarkeit prüfen

Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis

European journal of cancer (1990), 2017-02, Vol.72, p.S39-S40

2017

Link zum Volltext

Verfügbarkeit prüfen

OC-0345: Assessment of improved organ at risk sparing for meningioma for mixed or single photon and particle beam treatments

Radiotherapy and oncology, 2013-03, Vol.106, p.S135-S135

2013

Link zum Volltext

Verfügbarkeit prüfen

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

Cancer epidemiology, biomarkers & prevention, 2012-09, Vol.21 (9), p.1497-1509

2012

Link zum Volltext

Verfügbarkeit prüfen

2261P A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients

Annals of oncology, 2023-10, Vol.34, p.S1162-S1163

2023

Link zum Volltext

Verfügbarkeit prüfen

491P Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

Annals of oncology, 2023-10, Vol.34, p.S387-S387

2023

Link zum Volltext

Verfügbarkeit prüfen

79P Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients

Annals of oncology, 2020-05, Vol.31, p.S41-S41

2020

Link zum Volltext

Verfügbarkeit prüfen

886 - Changes in ctDNA levels established with the untargeted mFAST-SeqS method reflect response to therapy in metastasized breast cancer patients

European journal of cancer (1990), 2016-07, Vol.61, p.S205-S206

2016

Link zum Volltext

Verfügbarkeit prüfen

Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

Annals of oncology, 2019-10, Vol.30, p.v110-v111

2019

Link zum Volltext

Verfügbarkeit prüfen

320P - Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

Annals of oncology, 2019-10, Vol.30, p.v110-v111

2019

Link zum Volltext

Verfügbarkeit prüfen

Fünf Jahres Follow up einer Multicenter Studie über die kardiotoxische Sicherheit und Effektivität der neoadjuvanten Therapie mit liposomalem Doxorubicin (Myocet®), Docetaxel (Taxotere®) und Trastuzumab (Herceptin®) bei Patieninnen mit HER2-positivem Mammakarzinom

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (3)

2018

Link zum Volltext

Verfügbarkeit prüfen

172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)

Annals of oncology, 2020-05, Vol.31, p.S77-S78

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment

European journal of cancer (1990), 2018-04, Vol.92, p.S136

2018

Link zum Volltext

Verfügbarkeit prüfen

466 (PB-099) - Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment

European journal of cancer (1990), 2018-04, Vol.92, p.S136-S136

2018

Link zum Volltext

Verfügbarkeit prüfen

249 - Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis

European journal of cancer (1990), 2017-02, Vol.72, p.S39-S40

2017

Link zum Volltext

Verfügbarkeit prüfen

54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment

ESMO open, 2024-05, Vol.9, p.103061, Article 103061

2024

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-03-02: Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-03-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Soluble E-Cadherin as a Predictive Marker for Response to Preoperative Systemic Chemotherapy in Early Breast Cancer

Annals of oncology, 2014-05, Vol.25, p.i18-i18

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

On the microstructure control of the bendability of advanced high strength steels

On the correlation between fracture toughness and crash resistance of advanced high strength steels

Fracture Resistance of Advanced High-Strength Steel Sheets for Automotive Applications

Microstructural effects on fracture toughness of ultra-high strength dual phase sheet steels

Experimental issues in the instrumented 3 point bending VDA238-100 test

P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Changes in ctDNA levels established with the untargeted mFAST-SeqS method reflect response to therapy in metastasized breast cancer patients

Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis

OC-0345: Assessment of improved organ at risk sparing for meningioma for mixed or single photon and particle beam treatments

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

2261P A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients

491P Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

79P Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients

886 - Changes in ctDNA levels established with the untargeted mFAST-SeqS method reflect response to therapy in metastasized breast cancer patients

Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

320P - Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

Fünf Jahres Follow up einer Multicenter Studie über die kardiotoxische Sicherheit und Effektivität der neoadjuvanten Therapie mit liposomalem Doxorubicin (Myocet®), Docetaxel (Taxotere®) und Trastuzumab (Herceptin®) bei Patieninnen mit HER2-positivem Mammakarzinom

172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)

Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment

466 (PB-099) - Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment

249 - Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis

54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment

Abstract P6-03-02: Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer

Evaluation of Soluble E-Cadherin as a Predictive Marker for Response to Preoperative Systemic Chemotherapy in Early Breast Cancer

Suchergebnisse filtern